Clinical Trial

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-25.
Status change: Not Yet Recruiting → Recruiting 2025-12-15
Trial Details
NCT Number NCT06855069
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Ovarian Cancer
Enrollment 468 participants
Start Date 2025-03-13
Primary Completion 2027-03-07 (estimated)
Study Completion 2029-03-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-17